Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Chronic kidney disease · Advanced solid tumors

Bayer

Bayer AG

Bayer clinical programs — 47 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Kaiser-Wilhelm-Allee, Leverkusen, North Rhine-Westphalia 51373, DE HQ
97,894 Employees
EMA registrant Type
Company details
Status
Public
HQ
Kaiser-Wilhelm-Allee, Leverkusen, North Rhine-Westphalia 51373, DE
Employees
97,894
Programs
47
Drugs
62
Patents
5
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

Bayer projects

47 ClinicalTrials.gov programs sponsored by Bayer.

Bayer has 47 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

47 programs

Clinical programs

  1. 19920

    Bayer AG

    Proteinuria, Chronic kidney disease

    phase 3 small molecule active

    1 trial

  2. 20186

    Bayer AG

    Treatment of children with chronic kidney disease and proteinuria

    phase 3 small molecule active

    1 trial

  3. 21177

    Bayer AG

    Non-diabetic chronic kidney disease

    phase 3 small molecule active

    1 trial

  4. 21466

    Bayer AG

    Heart failure due to systemic left ventricular systolic dysfunction

    phase 3 small molecule active

    1 trial

  5. 21467

    Bayer AG

    Heart failure due to systemic left ventricular systolic dysfunction

    phase 3 small molecule active

    1 trial

  6. 22615

    Bayer AG

    Advanced non-small cell lung cancer with HER2 (ERBB2) mutation

    phase 3 small molecule active

    1 trial

  7. BAY 3427080, BAY 3427080 60 mg capsules placebo

    Bayer AG

    Vasomotor symptoms caused by adjuvant endocrine therapy in women with, or at high risk for developing hormone-receptor positive breast cancer

    phase 3 small molecule active

    1 trial

  8. BAY 94-9027/21824

    Bayer AG

    Severe hemophilia A (<1% FVIII:C)

    phase 3 small molecule active

    1 trial

  9. 12916

    Bayer AG

    "Patients with interstitial lung disease associated pulmonary hypertension"

    phase 2 other active

    1 trial

  10. 14308

    Bayer AG

    Patients symptomatic with pulmonary hypertension associated with left ventricular systolic dysfunction (PH-sLVD)

    phase 2 small molecule active

    1 trial

  11. 20289

    Bayer AG

    Solid tumors harboring NTRK fusion

    phase 2 small molecule active

    1 trial

  12. 20290

    Bayer AG

    Solid tumors harboring NTRK fusion

    phase 2 small molecule active

    1 trial

  13. 21839

    Bayer AG

    Chronic kidney disease in type 2 diabetes mellitus

    phase 2 small molecule active

    1 trial

  14. 22040

    Bayer AG

    Chronic kidney disease

    phase 2 small molecule active

    1 trial

  15. 22752

    Bayer AG

    HER2 mutation, Advanced solid tumors

    phase 2 small molecule active

    1 trial

  16. BAY 1021189

    Bayer AG

    Chronic heart failure with reduced ejection fraction

    phase 2 small molecule active

    1 trial

  17. BAY 2599023

    Bayer AG

    Hemophilia A

    phase 2 small molecule active

    1 trial

  18. BAY 3713372 Bayer for MTAP-deleted Solid Tumors

    Bayer AG

    MTAP-deleted Solid Tumors

    phase 2 small molecule active

    1 trial

  19. BAY 73-4506, BAY 734506

    Bayer AG

    Solid malignant tumors

    phase 2 small molecule active

    1 trial

  20. Placebo to BAY 3401016, BAY 3401016

    Bayer AG

    Alport Syndrome, Chronic kidney disease

    phase 2 small molecule active

    1 trial

  21. placebo of BAY 3427080, BAY 3427080

    Bayer AG

    Sleep disturbances associated with menopause

    phase 2 small molecule active

    1 trial

  22. 20511

    Bayer AG

    Prostate cancer

    phase 1 other active

    1 trial

  23. 21820

    Bayer AG

    Advanced solid tumors

    phase 1 other active

    1 trial

  24. 21948

    Bayer AG

    Advanced solid tumors

    phase 1 other active

    1 trial

  25. 22127

    Bayer AG

    Chronic kidney disease

    phase 1 other active

    1 trial

  26. 22128

    Bayer AG

    Chronic kidney disease

    phase 1 other active

    1 trial

  27. 22231

    Bayer AG

    Advanced solid tumors, Non-small cell lung cancer

    phase 1 other active

    1 trial

  28. 22262

    Bayer AG

    hepatocellular carcinoma (HCC)

    phase 1 other active

    1 trial

  29. 22265

    Bayer AG

    Coagulopathy, Sepsis

    phase 1 other active

    1 trial

  30. 22342

    Bayer AG

    Heart failure in children

    phase 1 other active

    1 trial

  31. 22375

    Bayer AG

    Prevention of ischemic stroke in patients after an acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack in combination with antiplatelet therapy

    phase 1 other active

    1 trial

  32. 22534

    Bayer AG

    Onchocerciasis (river blindness): is an infectious disease caused by Onchocerca volvulus, a parasitic nematode worm. The disease is contracted through the bite of an infected blackfly of the genus Simulium, which transmits third-stage infective larvae. An estimated 18 million people suffer from onchocerciasis, with 99% cases in 31 African countries, and 187 million people at risk Onchocercal dermatitis is the most common symptom of the disease, but severe visual impairment and blindness are the most severe complication, and onchocerciasis is the world’s second-leading infectious cause of blindness. Programs for the treatment and control of onchocerciasis through mass drug administration of ivermectin have been in place for over 20 years. However, they require patients to be given treatment (ivermectin) at regular intervals for the life of the adult worm (up to 15 years), making implementation extremely difficult in endemic countries. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug., Soil-transmitted helminth infection: Soil-transmitted helminthiasis is caused by one of the three soil-transmitted helminths (STH), Ascaris lumbricoides, Trichuris trichiura and hookworm (Ancylostoma duodenale and Necator americanus). Currently, STH still infects about 1.5 billion people worldwide, mostly in tropical and subtropical regions. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug.

    phase 1 other active

    1 trial

  33. 22537

    Bayer AG

    Soil-transmitted helminth infection, Onchocerciasis (river blindness)

    phase 1 other active

    1 trial

  34. 22597

    Bayer AG

    Chronic kidney disease, Coronary artery disease

    phase 1 other active

    1 trial

  35. 22598

    Bayer AG

    Chronic Kidney Disease, Arterial hypertension

    phase 1 other active

    1 trial

  36. 22600

    Bayer AG

    Chronic Kidney Disease

    phase 1 other active

    1 trial

  37. 22665

    Bayer AG

    Prevention of ischemic stroke in patients post acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack

    phase 1 other active

    1 trial

  38. 22676

    Bayer AG

    Advanced solid tumors harboring KRAS G12C mutation

    phase 1 other active

    1 trial

  39. 22700

    Bayer AG

    Chronic Kidney Disease

    phase 1 other active

    1 trial

  40. 22723

    Bayer AG

    Chronic kidney disease

    phase 1 other active

    1 trial

  41. 22806

    Bayer AG

    atrial fibrillation, transient ischemic attack (TIA), ischemic stroke

    phase 1 other active

    1 trial

  42. 22819

    Bayer AG

    Cardiac arrhythmia

    phase 1 other active

    1 trial

  43. 22967

    Bayer AG

    Vasodilatory shock

    phase 1 other active

    1 trial

  44. A study to learn how safe the study drug BAY... for Advanced solid tumors

    Bayer AG

    Advanced solid tumors

    phase 1 other active

    1 trial

  45. Asundexian Bayer 10mg Granules, BAY 2433334

    Bayer AG

    Prevention of thromboembolic events

    phase 1 small molecule active

    1 trial

  46. 20510

    Bayer AG

    metastatic castrate resistant prostate cancer (mCRPC)

    approved small molecule active

    1 trial

  47. Eylea 114.3 mg/ml solution for injection

    Bayer AG

    Neovascular age-related macular degeneration (nAMD), Diabetic macular edema (DME)

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Bayer have?

47 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.